HOLX 26.46 Hologic Inc $HOLX Hit a 52 week high of
Post# of 35
HOLX Recent Posts: http://investorshangout.com/Hologic-Inc-HOLX-54363/
HOLX Hologic Inc Recent Headline News
Hologic tops Street 4Q forecasts
Automated Insights - Wed Nov 05, 3:31PM CST
BEDFORD, Mass. (AP) _ Hologic Inc. (HOLX) on Wednesday reported earnings of $28.2 million in its fiscal fourth quarter.
HOLX: 26.46 (-0.58)
Hologic Announces Fourth Quarter Fiscal 2014 Operating Results
PR Newswire - Wed Nov 05, 3:01PM CST
Hologic, Inc. (NASDAQ: HOLX) announced today its results for the fourth fiscal quarter ended September 27, 2014.
HOLX: 26.46 (-0.58)
The Centers for Medicare and Medicaid Services Issues Ruling on 2015 Reimbursement Rates
PR Newswire - Fri Oct 31, 9:28PM CDT
Hologic, Inc. (NASDAQ: HOLX) announced today that the Centers for Medicare and Medicaid Services (CMS) has released reimbursement rates for screening and diagnostic 3D mammography. The action establishes national average payment rates for the Category I Current Procedural Terminology (CPT) code for 3D screening mammography and creates a new add-on Healthcare Common Procedure Coding System (HCPCS) code for 3D diagnostic mammography.
HOLX: 26.46 (-0.58)
Health Care Equipment Stocks Technical Insight - Medtronic, Abbott Laboratories, Hologic, ResMed, and Covidien
PR Newswire - Fri Oct 31, 8:05AM CDT
Investor-Edge has initiated coverage on the following equities: Medtronic Inc. (NYSE: MDT), Abbott Laboratories (NYSE: ABT), Hologic Inc. (NASDAQ: HOLX), ResMed Inc. (NYSE: RMD), and Covidien PLC (NYSE: COV). Free research on these five companies can be accessed at: http://investor-edge.com/register. The US markets on Thursday, October 30, 2014, ended on a positive note as the Dow Jones Industrial Average finished at 17,195.42, up 1.30% and the NASDAQ Composite closed at 4,566.14, up 0.37%. The S&P 500 finished the session 0.62% higher at 1,994.65. During the trading session, nine out of ten sectors finished on a higher note. The S&P 500 Health Care Sector Index ended the day at 774.91, up 1.81%, with the index gaining 7.78% in the previous three months. Register for your complimentary reports on these five stocks at:
ABT: 43.66 (+0.05), MDT: 68.70 (+0.77), COV: 93.32 (+1.29), RMD: 51.45 (-0.36), HOLX: 26.46 (-0.58)
Is Haemonetics (HAE) Poised to Beat on Q2 Earnings? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Oct 30, 5:15PM CDT
Haemonetics (HAE) has delivered positive earnings surprises in three of the past four quarters with an average beat of 1.9%
HAE: 36.42 (+0.93), HTWR: 77.34 (+0.20), HOLX: 26.46 (-0.58), HSP: 53.10 (-0.18)
Can Qiagen (QGEN) Surprise Earnings Estimates in Q3? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Oct 28, 5:17PM CDT
In Japan, Qiagen (QGEN) performed impressively in the first half of 2014 on a year-over-year basis.
QGEN: 23.53 (-0.17), HTWR: 77.34 (+0.20), HOLX: 26.46 (-0.58), HSP: 53.10 (-0.18)
Luminex Tops Q3 Earnings, Revenues in Line; Outlook Weak - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Oct 28, 12:40PM CDT
Luminex Corporation's (LMNX) earnings per share jumped sharply to 22 cents from a penny in the year-ago quarter driven by strong revenue growth and margin expansion.
BDX: 127.22 (+0.88), LMNX: 18.85 (+0.03), AFFX: 9.50 (+0.11), HOLX: 26.46 (-0.58)
Upgrade Alert for Hologic (HOLX)
Comtex SmarTrend(R) - Tue Oct 28, 6:58AM CDT
Hologic (NASDAQ:HOLX) was upgraded from Hold to Buy at Craig-Hallum today. The stock closed yesterday at $25.21 on volume of 2.5 million shares, below average daily volume of 2.7 million. Over the past year, Hologic has traded in a range of $13.90 to $26.75 and closed yesterday at $25.21, 81% above that low. Over the last five market days, the 200-day moving average (MA) has gone up 0.2% while the 50-day MA has declined 0.2%.
HOLX: 26.46 (-0.58)
Can Ecolab Inc. (ECL) Surprise This Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Oct 27, 2:58PM CDT
Our proven model does not conclusively show that Ecolab Inc. (ECL) is likely to beat earnings this quarter.
HTWR: 77.34 (+0.20), HOLX: 26.46 (-0.58), HSP: 53.10 (-0.18), ECL: 110.46 (+1.11)
Is LabCorp (LH) Likely to Disappoint Earnings in Q3? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Oct 27, 2:20PM CDT
Laboratory Corp. of America Holdings (LH) is scheduled to release its third-quarter 2014 results before the opening bell on Oct 28.
LH: 102.21 (-0.17), HTWR: 77.34 (+0.20), HOLX: 26.46 (-0.58), HSP: 53.10 (-0.18)
Axial and Peripheral Bone Densitometers - 2014 Global Strategic Business Report.
M2 - Fri Oct 24, 8:54AM CDT
Research and Markets (http://www.researchandmarkets.com/research/s3fz9n/bone) has announced the addition of the "Bone Densitometers - Global Strategic Business Report." report to their offering. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Middle East, and Latin America. Annual estimates and forecasts are provided for the period 2013 through 2020. Also, a seven-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 18 companies including many key and niche players. This report analyzes the worldwide markets for Bone Densitometers in Units and US$ Thousands by the following Product Segments: - Axial Bone Densitometers - Peripheral Bone Densitometers Key Topics Covered: I. Introduction, Methodology & Product Definitions II. Executive Summary 1. Industry Overview 2. Competitive Factors 3. Reimbursements: Vital For Market Expansion 4. Product Overview 5. Osteoporosis: An Overview 6. Bone Densitometry Alternatives 7. Osteoporosis Drug Market - Impact On Diagnostics 8. Recent Industry Activity 9. Focus On Select Players 10. Global Market Perspective III. Market 1. The United States 2. Canada 3. Japan 4. Europe 5. Asia-Pacific 6. The Middle East 7. Latin America IV. Competitive Landscape - Total Companies Profiled: 18 (including Divisions/Subsidiaries - 19) - The United States (5) - Japan (1) - Europe ( - - France (2) - - Germany (1) - - The United Kingdom (1) - - Italy (1) - - Spain (1) - - Rest of Europe (2) - Asia-Pacific (Excluding Japan) (4) - Middle East (1) Companies Mentioned - Beammed Ltd. - CompuMed, Inc. - GE Healthcare - Hologic, Inc. - Lone Oak Medical Technologies, LLC For more information visit http://www.researchandmarkets.com/research/s3fz9n/bone
HOLX: 26.46 (-0.58)
The Zacks Analyst Blog Highlights: Edwards Lifesciences, Hospira, Hologic and Heartware International
PR Newswire - Thu Oct 23, 8:30AM CDT
Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the Edwards Lifesciences Corp. (NYSE:EW-Free Report), Hospira Inc. (NYSE:HSP-Free Report), Hologic Inc. (Nasdaq:HOLX-Free Report) and Heartware International Inc. (Nasdaq:HTWR-Free Report).
EW: 121.10 (+1.32), HOLX: 26.46 (-0.58)
Can Quality Systems (QSII) Surprise This Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Oct 22, 3:20PM CDT
Our proven model does not conclusively show that Quality Systems Inc. (QSII) is likely to beat earnings this quarter.
PACB: 6.34 (-0.23), QSII: 14.98 (unch), HTWR: 77.34 (+0.20), HOLX: 26.46 (-0.58)
Can Edwards Lifesciences (EW) Surprise Earnings in Q3? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Oct 22, 2:30PM CDT
Edwards Lifesciences (EW) has delivered positive earnings surprises in all the past four quarters with an average beat of 9.7%
EW: 121.10 (+1.32), HTWR: 77.34 (+0.20), HOLX: 26.46 (-0.58), HSP: 53.10 (-0.18)
Genetic Testing Market Outlook 2018 Featuring the Ten Most Active Genetic Testing Market Players Worldwide
M2 - Wed Oct 22, 9:09AM CDT
Research and Markets (http://www.researchandmarkets.com/research/twtv8n/genetic_testing) has announced the addition of the "Genetic Testing Market Outlook 2018" report to their offering. A recent report, Genetic Testing Market Outlook 2018, provides an in-depth analysis of the current and future genetic testing market. A comprehensive introduction of gene-based tests, their working principles and types are covered in this report. On account of our analysis of the past and present market trends; drivers; and existing strengths and challenges; forecast for genetic testing has been drawn, according to which, the market is likely to grow at a CAGR of around 9% during 2013-2018. Our report is an outcome of extensive interaction with industry experts which has led us to portray the updated status of genetic testing in various therapeutic areas, major geographies and significant industry applications. The genetic testing industry has seen several new product launches, active research innovations, strategic activities, launch of new DTC tests, and wider therapeutic applications. The report effectively illustrates the role of genetic testing in diseases such as Cancer, Cystic Fibrosis, and Alzheimer. It also incorporates the information on disease prevalence, available tests, and genes that cause a particular disease. An extensive research and reliable statistics in terms of market size, developments and future performance for emerging sectors namely, Next-Generation Sequencing, Whole Genome Sequencing, Non Invasive Prenatal Diagnostics, and Personalized Medicine have been covered in the report. Genetic testing is growing in both developing and developed nations with both industry and research personnel highlighting the significance of molecular biology. The report provides comprehensive analytics of key developments for major markets including the U.S., Europe and Asian countries, and their market overview. Country level analysis depicts the level of penetration for genetic testing, types of tests available, consumer perspectives, regulatory stringency and future growth. The report also profiles the ten most active genetic testing market players worldwide: Abbott Laboratories, Roche Diagnostics, Myriad Genetics, Life Technologies, Agilent, Hologic, Illumina, Qiagen, Cepheid, and Affymetrix. Key Topics Covered: 1. Analyst View 2. Research Methodology 3. Genetic Testing Overview 4. Global Genetic Testing Market Overview 5. Disease-Wise Analysis 6. Country-Level Analysis 7. Emerging Sectors 8. Genetic Testing Regulation 9. Competitive Assessment - Abbott Laboratories - Affymetrix, Inc. - Agilent Technologies Inc. - Cepheid - Hologic, Inc. - Illumina, Inc. - Life Technologies Corporation (Thermo Fisher Scientific) - Myriad Genetics, Inc. - Qiagen NV - Roche Diagnostics For more information visit http://www.researchandmarkets.com/research/tw...ic_testing
ABT: 43.66 (+0.05), MYGN: 34.61 (-2.28), A: 40.13 (-0.05), CPHD: 52.44 (-0.08), ILMN: 186.37 (-5.04), HOLX: 26.46 (-0.58), AFFX: 9.50 (+0.11)
Can Cerner Corp. (CERN) Surprise This Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Oct 21, 5:45PM CDT
Our proven model does not conclusively show that Cerner Corporation (CERN) is likely to beat earnings this quarter.
PACB: 6.34 (-0.23), HTWR: 77.34 (+0.20), HOLX: 26.46 (-0.58), CERN: 63.20 (-0.28)
Will Varian Medical Systems (VAR) Miss Earnings Estimates? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Oct 21, 12:10PM CDT
For the fourth quarter of fiscal 2014, Varian Medical Systems (VAR) expects revenues to increase in the range of 7 to 15%.
VAR: 84.41 (+0.10), HTWR: 77.34 (+0.20), HOLX: 26.46 (-0.58), HSP: 53.10 (-0.18)
Is Thermo Fisher (TMO) Poised to Surprise Q3 Earnings? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Oct 20, 1:50PM CDT
Last quarter, Thermo Fisher Scientific, Inc. (TMO) had delivered a 6.17% positive surprise.
PACB: 6.34 (-0.23), TMO: 118.55 (+0.23), HTWR: 77.34 (+0.20), HOLX: 26.46 (-0.58)
Look Down!; Jump of a Lifetime; Not for the Faint of Heart: Best of Kass
at The Street - Sun Oct 19, 3:21PM CDT
In highlights from his trading diary of the past week, Doug Kass writes about how investors aren't looking in the right direction and frustration with such a volatile market.
NFLX: 380.38 (-2.40), HLF: 39.78 (-4.48), GE: 25.82 (+0.12), HTZ: 21.12 (+0.27), TLM: 5.52 (+0.16), RIG: 28.89 (+1.54), EBAY: 53.58 (+0.31), NUAN: 15.57 (+0.05), CHK: 22.76 (+1.47), IEP: 103.37 (+0.06), AAPL: 108.86 (+0.26), HOLX: 26.46 (-0.58)
Will Intuitive Surgical (ISRG) Beat Q3 Earnings Estimates? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Oct 17, 1:40PM CDT
Our proven model does not conclusively show that Intuitive Surgical, Inc. (ISRG) is likely to beat earnings this quarter.
ISRG: 505.37 (+9.37), ABAX: 54.45 (+1.07), HTWR: 77.34 (+0.20), HOLX: 26.46 (-0.58)